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We read with great interest the article by Mateo et al. [1] on
the management of nonmetastatic castration-resistant
prostate cancer. The PROSPER (NCT02003924) [2] and the
SPARTAN (NCT01946204) [3] trials showed that enzaluta-
mide and apalutamide improve metastasis-free survival
(MFS) among patients without evidence of metastasis on
conventional radiological imaging (computed tomography
and bone scans). Since February 2019, data from the
ARAMIS trial (NCT02200614) have become available [4],
with similar MFS outcomes for darolutamide as for
enzalutamide and apalutamide. It should be noted that
the safety profile of darolutamide is promising because of
its low penetration across the blood-brain barrier and low
binding affinity for g-aminobutyric acid type A receptors, as
shown in preclinical studies.
However, the safety of darolutamide seems to be better
than its actual effectiveness. In the PROSPER trial of
enzalutamide [2], there was a hazard ratio of 0.29 for
metastasis or death among a series of patients with a
prostate-specific antigen (PSA) doubling time of 3.8 mo. The
ARAMIS trial [4], in which there was a hazard ratio of
0.41 ratio for metastasis or death, enrolled patients with a
longer PSA doubling time (4.4 mo) [1]. Could this dissimilar-
ity be regarded as the reason for the discrepancy, or would a
few weeks make such a difference in an aggressive setting?
A 6-mo threshold for PSA doubling time has long been
considered a landmark: a shorter PSA doubling time is
associated with a trend towards greater detection of
metastasis via prostate-specific membrane antigen–based
positron emission tomography (83% vs 60% for PSA doubling
time of <6 mo vs >6 mo) [5].
Since biological aggressiveness below the 6-mo thresh-
old has rarely been investigated, what would we expect in
the case of a shorter PSA doubling time? Despite thePlease cite this article in press as: Rocco B, Sighinolfi MC. Re: 
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with more aggressive disease, as evidenced by data for
patients assigned to the placebo group. The time to PSA
progression in the placebo arm was shorter in the PROSPER
trial (3.8 mo) than in the ARAMIS trial (7.3 mo), suggesting a
more pronounced impact of enzalutamide, even for patients
at higher risk of progression.
Safety and easy handling should complement the
effectiveness of new hormonal agents; this issue should
be further addressed before formulating recommendations
based on drug toxicity.
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